A genotoxin is a chemical or agent that can cause DNA or chromosomal damage. Such damage in a germ cell has the potential to cause a heritable altered trait (germline mutation). DNA damage in a somatic cell may result in a somatic mutation, which may lead to malignant transformation (cancer). Many in-vitro and in-vivo tests for genotoxicity have been developed that, with a range of endpoints, detect DNA damage or its biological consequences in prokaryotic (e.g. bacterial) or eukaryotic (e.g. mammalian, avian or yeast) cells. These assays are used to evaluate the safety of environmental chemicals and consumer products and to explore the mechanism of action of known or suspected carcinogens. Many chemical carcinogens/mutagens undergo metabolic activation to reactive species that bind covalently to DNA and the DNA adducts thus formed can be detected in cells and in human tissues by a variety of sensitive techniques. The detection and characterisation of DNA adducts in human tissues provides clues to the aetiology of human cancer.
Introduction
Cancer is a genetic disease arising from a series of somatic mutations. Mutations in DNA may arise spontaneously, or as a result of chemical action by agents of either endogenous or exogenous origin. Genetic toxicology is the study of agents that can damage the DNA and chromosomes of cells. In eukaryotic organisms, genetic damage in somatic cells may lead to malignancy. In germ cells it may adversely affect reproduction or provoke heritable mutations.
Consequently, investigating the genotoxicity of a compound is often carried out in the context of seeking to understand its mechanism of carcinogenicity and this has become an essential component of the process of risk assessment for human exposure to a known animal carcinogen. Investigating genotoxicity is also important in assessing whether or not a new compound is a carcinogen and/or mutagen, and this process contributes to the more fundamental process of hazard identification.
Understanding mechanisms of carcinogenesis often relies on analysis of the molecular and cellular effects of carcinogens in laboratory experiments. This is a necessary simplification of a complex process and while such approaches often provide critical evidence for mechanisms, it must be recognised that laboratory models rarely cover all the possible facets of the process, and there are many instances in which the classification of a carcinogen is not a straightforward matter.
A genotoxic carcinogen typically induces tumours in multiple organs of rodents, may be carcinogenic to more than one species and to both males and females. In addition, there is often evidence of a dose-response relationship for tumour induction, of the type that does not suggest evidence of a threshold. In contrast, non-genotoxic carcinogens are more likely to be characterised by tumour induction in a single species and/or in a single tissue and, commonly, in one sex only, often at low incidence and only at high dose with associated evidence of toxicity. Multi-species, multi-organ carcinogens are more likely to be human carcinogens and, indeed, most agents classified as human carcinogens by the International Agency for Research on Cancer (IARC) are genotoxic. It is thus a general principle that chemicals that are carcinogenic in animals by a genotoxic mechanism pose a greater potential risk to humans than non-genotoxic carcinogens, and the default assessment of genotoxins is that human exposure at any level poses a risk. For such agents exposure should be As Low As Reasonably Achievable (ALARA). For non-genotoxic carcinogens it may be possible to define a threshold, i.e. a level of exposure below which the agent does not present a carcinogenic risk to humans.
In some animal models carcinogenicity can be divided into an initiation phase, involving a single treatment with a genotoxic agent, followed by promotion, involving repeated treatments with a non-genotoxic agent. A common feature is that initiation is considered irreversible, such that the promotion phase can be delayed significantly yet still ultimately result in tumour formation.
Furthermore the tumour response may be absent or greatly reduced if the initiator is applied after the promoter, or if treatment is with either initiator or promoter alone. Although this model of initiation and promotion has served well as an experimental system for defining genotoxicity and for some studies of mechanisms of tumour formation, it appears to present an over-simplification of the process, particularly when considering the mechanism(s) of carcinogenesis in humans.
Epidemiological evidence on the age distribution of many common cancers suggested that cancer induction is a multi-stage process, involving as many as 5-7 distinct events [1] . Although this conclusion was reached more than 50 years ago, before anything was known about the changes associated with malignancy were identified or understood, genetic analysis of tumours over the last 10 or more years has borne out this out. Current understanding is that the accumulation of a number of mutations (5-7 is a reasonable estimate) in critical genes in progenitor cells leads to the manifestation of the malignant phenotype.
Phenotypically, malignancy is characterised by six essential alterations in cell physiology:
(i) self-sufficiency in growth signals, (ii) insensitivity to growth-inhibitory signals, (iii) evasion of programmed cell death (apoptosis), (iv) limitless replicative potential, (v) angiogenesis and (vi) tissue invasion and metastasis [2] . Although there is not yet an exact match between the genotypic and phenotypic characteristics of tumours, it is logical to conclude that carcinogenesis is driven by the accumulation of critical mutations in cells that converts them and their progeny from normal cells to fully malignant ones. The identification of mutations in specific genes in human cancers has demonstrated that they are associated with both early and late stages of tumour progression [3] .
Thus, while it is thought that DNA damage (often involving binding to DNA by carcinogens) occurs in the early, initiating stages of carcinogenesis, it is probable that genotoxic events are also a feature of later stages of the multistage process, now that it is apparent that gene mutation is associated with several stages of carcinogenesis.
Short-term tests for genotoxicity
In the context of short-term tests for mutagenicity and genotoxicity, a genotoxic agent is one that induces point mutations, deletions, insertions, gene amplifications, chromosomal rearrangements or numerical chromosomal changes (aneuploidy). The tests are therefore designed to detect one or more type of genetic alteration. Since such biological properties result directly or indirectly from DNA damage, other assays have been developed to identify this damage directly.
No single assay, no matter how extensive the protocol, can detect all genotoxic chemicals [4] . Therefore, it is generally accepted that a number of tests must be conducted to evaluate whether a chemical is genotoxic or not, and often a weight-of-evidence approach must be taken to evaluate the results.
A number of organisations and advisory bodies have produced guidelines in the last ten years. These include the International Programme on Chemical Safety (IPCS), the International
Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for
Human Use (ICH), and the International Workshop on Genotoxicity Testing (IWGT). These and other guidelines have been reviewed and compared by Cimino [5] .
For a test to be useful it should be both sensitive and specific (see Table 1 ). Several guidelines recommend that a test battery for genotoxicity should include: 1) a test for gene mutation in bacteria; 2) an in-vitro test that includes cytogenetic evaluation of chromosomal damage in mammalian cells or an in-vitro mammalian cell mutagenicity test such as the mouse lymphoma Tk assay; 3) an in-vivo test for chromosomal damage using rodent haematopoietic cells. Some guidelines advise that negative results in both of the first two assays may in some cases (e.g. a lowvolume chemical where the potential for human exposure is minimal) remove the necessity of conducting the third, in-vivo, test. More recently, however, the Seventh Amendment to the European Union Cosmetics Directive that will ban the marketing of cosmetics and personal care products containing ingredients tested in animals has highlighted the need for better in-vitro tests for toxicity and genotoxicity [6] .
Bacterial mutagenicity testing
The most widely used bacterial assay to detect chemically-induced gene mutations is the Ames Salmonella assay developed by Bruce Ames [7; 8] . Salmonella typhimurium strains that contain defined mutations in the histidine locus form the basis of this 'reverse' mutation assay. In the assay, bacteria are incubated with a range of concentrations of the test compound to induce a second mutation that directly reverses or suppresses the original mutations and, thus, restores the biological function to the non-functional histidine gene. Strains of S. typhimurium used in the Ames assay are auxotrophic for histidine and revertants are selected by their ability to grow in the absence of this amino acid. Two of the most commonly used S. typhimurium strains are TA98 and TA100. S. typhimurium TA98 has a hisD3052 mutation detecting frame-shift reversion events whereas S. typhimurium TA100 has a hisG46 mutation detecting base-pair substitution events [9] . The great strength of the assay is the ability to identify and score a small number of mutants from a relative large population of unmutated cells. However, as bacteria lack many endogenous metabolic pathways that are required for the bioactivation of the test chemicals, extracts of mammalian liver (usually rat) are incorporated as an exogenous activation system [9] . Fractionated tissue homogenate such as the 9000 g supernatant (S9 fraction), prepared from the livers of rats pretreated with Aroclor 1254, provides a rich source of mixed-function mono-oxygenases required for bioactivation.
The Ames assay can either be used to assess the mutagenic potency of a chemical as part of the toxicological screening, or else it can form part of a detailed mechanistic examination of the chemical's mutagenic potential. In the current ICH and OECD Guidelines, the use of 5 tester strains is recommended: TA98, TA100 and TA1535; TA1537 or TA97 or TA97a; TA100 (or alternatively one of several Escherichia coli WP2 strains). In order to make the assay more sensitive, these strains contain an rfa mutation resulting in defective lipopolysaccharide and increased permeability to large test molecules, or a deletion in the uvrB gene making the strains deficient in nucleotide excision repair. Some strains (e.g. S. typhimurium TA98 and TA100) include additionally a plasmid (pKM101) containing umuDC genes encoding for a translesion-synthesis DNA polymerase that elicits error-prone repair [10] . Using genetically-engineered S. typhimurium strains that either overexpress or lack enzymes required for the bioactivation of different carcinogens can provide useful information on their metabolism [11; 12] . Moreover, 'humanised' S. typhimurium strains with defined human enzymes have been developed in order to identify which human enzymes are involved in bioactivation and to improve the relevance of Ames Salmonella assay for detecting agents hazardous to humans [13] .
Mammalian mutagenicity testing
The mouse lymphoma assay (MLA) is the most widely used mammalian gene mutation assay [14] . It detects various mutation events involving the thymidine kinase (Tk) gene in L5178Y/Tk +/− 3.6.2C mouse lymphoma cells [15; 16] . The gene coding for thymidine kinase is on mouse chromosome 11 and allows the cell to salvage nucleotides from the culture medium for reuse in metabolism but is not essential for cell survival. Since eukaryotic cells are diploid, heterozygous cells are used where two copies of the Tk gene are present but one copy has been inactivated.
Otherwise, many mutations arising in mammalian cells cannot be selected directly, since the second copy of the gene would complement the first. Mutants in the MLA are detected by plating cells into medium containing trifluorothymidine (TFT), a thymidine analogue [17] . Thus, toxic TFT placed in the medium will be transported into normal Tk +/− (non-mutated) cells that consequently die, while Tk −/− mutants will be resistant to the toxic TFT and survive, and subsequently form clones that can be counted. The L5178Y system is the recommended in-vitro mammalian cell mutation assay because it detects a wide range of genetic alterations, including both mutations and chromosomal damage [18] .
Transgenic rodent mutation assays
Transgenic rodent mutation assays were first developed in the 1990s [19; 20] , Muta™Mouse and Big Blue® Mouse and Rat being the assays most widely used [21; 22] . Muta™Mouse carry a recombinant λ-bacteriophage vector containing the entire Escherichia coli lacZ (β-galactosidase) [21] . Mutations occurring in the lacZ gene are measured by positive selection of lacZ − mutants on phenylgalactosidase (P-gal)-containing medium using an indicator bacteria strain (E. coli lacZ − galE − ). In the presence of P-gal only lacZ − bacteria (mutants) will grow and produce plaques, whereas lacZ + (i.e. non-mutants) produce the enzyme β-galactosidase converting P-gal into galactose and subsequently into the toxic intermediate uridine diphosphate (EDP)-galactose, which accumulates in E. coli galE − and kills the cells. In the Big Blue® system, the reporter gene is lacI contained in a λ-bacteriophage vector [22] . Mutants occurring in the lacI gene are selected on 5bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal)-containing medium using an E. coli lacI − indicator strain. Wild-type lacI (non-mutants) will repress the lac operon encoding for β-galactosidase forming clear plaques whereas lacI − mutants will produce β-galactosidase that uses X-gal as substrate producing blue coloured plaques that can be counted. Since the 'reporter' genes that serve as targets for detecting mutations are incorporated into the chromosomes of the transgenic mice or rats, somatic mutations can be measured within any tissue of the exposed animal, and more importantly enables mutation induction and measurement in the actual target tissue for tumour development. General guidance on recommended protocols has been published [23; 24] .
The lacI/lacZ models are well suited to detect point mutations but unsuited for the detection of large deletion mutations induced by clastogens [19] . However, the coding size of, for instance, the lacZ gene is about 3 kb (kilo base pairs), which is not compact enough to routinely identify mutations by DNA sequencing. Thus, a new reporter gene, the cII gene of the λ phage, has been used and is applicable to both Muta™Mouse and Big Blue® Mouse systems [25] . The cII gene is susceptible to mutagenesis, just as is lacI or lacZ, but has the advantage over them that the coding region is only 300 base pairs and can easily be sequenced in a single run. An alternative transgenic mouse model, gpt delta, is reported to be suitable for the detection of large deletions [26] .
Tests for chromosome damage
Structural chromosome changes that can be detected by conventional in-vitro cytogenetics are chromosome aberrations (CA), micronuclei (MN) and sister chromatid exchanges (SCE).
Structural CA are changes in normal chromosome structure or number that can occur in cells after chemical exposure or radiation. They result from direct DNA breakage, replication on a damaged DNA template, inhibition of DNA synthesis, and other mechanisms (e.g. inhibition of topoisomerase II) [27] . Cells commonly used to measure structural CA are human peripheral blood lymphocytes or established lymphoblastoid cell lines [28] . Peripheral lymphocytes are popular cells for in-vitro studies because they are human primary cells, have a low spontaneous rate of chromosomal damage, and can be easily cultured with a stable karyotype (2n=46). Structural CA are generally scored in metaphase-arrested cells after Giemsa staining [29] . For over 30 years structural CA in human peripheral blood lymphocytes have been used in occupational and environmental settings as a biomarker of exposure and a marker of cancer risk [30; 31] .
The in-vitro micronucleus test allows the detection of both structural (clastogenic) and numerical (aneugenic) chromosome changes using interphase cells [32] . Thus, MN represents a measure of both chromosome breakage and chromosome loss, and an increased frequency of micronucleated cells is a biomarker of genotoxic effects. MN formed by clastogenicity induction can be distinguished from those produced by aneugenic activity by the absence of centrometric DNA or kinetochore proteins in the MN using centrometric probes or kinetochore antibodies [33] .
The standard in-vitro micronucleus test is usually performed in lymphocytes [34] , the cytokinesisblock micronucleus assay being the most widely used method. This assay is specifically restricted to once-divided cells and these cells are recognised by their binucleated appearance after inhibition of cytokinesis by cytochalasin-B [35] . Restricting the scoring of MN to binucleate cells prevents confounding effects that can be a major variable in the assay. The use of MN as a measure of chromosomal damage has become a standard assay both in genotoxicity testing (although an OECD guideline protocol has yet to be adopted) and human biomonitoring studies [36; 37] .
The rodent micronucleus test is a widely used and extensively validated assay to assess chromosome damage in vivo and has been incorporated into standard rodent toxicology screening assays [38; 39] . For the analysis, immature erythrocytes (i.e., polychromatic erythrocytes; reticulocytes) in either bone marrow or peripheral blood have been found equally acceptable when the rodents have been exposed to the test compound by an appropriate route. A detailed description of the study design and experimental procedure has been published [39; 40] .
Comet assay
The comet assay (or single-cell gel electrophoresis assay) is a simple and sensitive method for measuring alkali labile sites and DNA strand breaks in the DNA of mammalian cells [41] . In the assay, a small number of cells suspended in agar are lysed under alkaline conditions, subjected to electrophoresis, neutralised and stained with a fluorescent DNA dye, such as propidium iodide [42; 43] . Cells with increased DNA damage display increased migration of the chromosomal DNA from the nucleus resembling the shape of a 'comet'. Using image analysis software parameters such as percentage of DNA in the tail (percent migrated DNA), tail length, and tail moment (fraction of migrated DNA multiplied by some measure of tail length) can be determined as a measure of DNA damage. As an in-vivo genotoxicity assay, it has the advantage that it can be applied to a single-cell suspension of material from any animal tissue, allowing consideration of potential target tissues and also taking account of possible inaccessibility to exposure of tissues (e.g. bone marrow) required for other in-vivo assays.
Under alkaline conditions, the assay detects overt strand breaks, which can include single and double strand breaks, as well as transient repair-induced breaks. It also detects lesions that are alkali-labile, which includes AP (apurinic/apyrimidinic) sites (see below). More precise information on the nature of the lesions detected can be obtained by the inclusion of lesion-specific endonucleases in the assay protocol, which convert some types of DNA damage to strand breaks [44] . Formamidopyrimidine-DNA-glycosylase (FPG) has been used to detect oxidised DNA damage, principally 8-oxo-dGuo (7, 8-dihydro-8-oxo-2'-deoxyguanosine), with high sensitivity [45] . More recently, it has been reported that FPG also detects some types of alkylation damage, and that the human homologue of FPG, hOGG1, is a more specific endonuclease for oxidation products [46] . Another enzyme, endonuclease III, converts oxidised pyrimidines to strand breaks [44] .
The comet assay is used in many studies to assess DNA damage and repair and has widespread application in genotoxicity testing in vitro and in vivo [47] . Since virtually any cell population or single-cell suspension from any tissue type can be used for analysis, the assay in widely used in environmental biomonitoring and human population monitoring [44; 48; 49] .
Correlations of mutagenicity and carcinogenicity
Clearly a major purpose of conducting the foregoing assays is to be able to predict whether or not a chemical is a carcinogen without conducting a costly and time-consuming animal bioassay.
The reliability of such tests, both in terms of the specificity and selectivity, is a matter of ongoing debate, subject to the continual accumulation of new data. Where a compound known to be carcinogenic is not detected as a mutagen or genotoxin in such assays, or where a mutagen (or genotoxin) has been found to be non-carcinogenic, some sort of explanation needs to be sought. A carcinogen may be non-mutagenic or non-genotoxic because its mechanism of action does not involve DNA damage (i.e. it is a non-genotoxic carcinogen that may, for example, act as a tumour promoter or by inhibiting DNA methylation). On the other hand it may be that mutagenic activity of the genotoxic carcinogen is limited to the chromosomal level, or that unusual metabolic activation for activity is required and that this is not achieved in the in-vitro test. The addition of external enzymatic activation systems (e.g. rat liver S9) may not be adequate for some compounds, particularly where phase II enzymes are required or where the half-life of the reactive species may be short or its cell permeability limited. Strategies to overcome these shortcomings include the use of human liver S9 [50] and the engineering of bacteria or mammalian cells to express human xenobiotic metabolising genes [13; 51] , but these approaches are, as yet, research tools and not part of the regulatory armoury.
Non-carcinogens may test positive as mutagens if the activity in the test system is due to a metabolic pathway not exhibited in vivo or due to the absence of a competing detoxification pathway or lack of DNA repair; or it may be that mutagenicity is limited to a particular type of genetic damage (e.g. aneuploidy). Alternatively it may be that mutagenicity is insufficient for carcinogenicity, which may require accompanying cell proliferation in the target tissue; or it may simply be that the in-vivo rodent models used for carcinogenicity testing may not be sufficiently sensitive for some weak mutagens.
As stated earlier, it is widely recognised that no single assay can detect all genotoxic carcinogens, hence the evolution of the standard battery of tests. But even then, there are some genotoxins that go undetected by all these assays [52] .
DNA adducts formed by chemical carcinogens
Genotoxic chemical carcinogens are either directly or indirectly DNA reactive. Most chemical carcinogens are not chemically reactive as such, but undergo metabolic activation in mammalian cells to reactive intermediates that react with DNA (Table 2) DNA adducts can also originate from endogenous processes, including normal metabolism, oxidative stress and chronic inflammation [53] . The most abundant oxidation lesion in DNA is 8oxo-dGuo, which can be formed by free radical attack on DNA or through normal aerobic metabolism. It is suspected that some genotoxic carcinogens that do not appear to directly modify DNA instead damage it through inducing oxidative stress leading to increased oxidative damage to DNA.
In experimental studies where multiple doses of carcinogens have been administered to animals and both tumour outcome and DNA adduct levels have been determined, there has in general been found to be a linear relationship between dose and both these parameters at low dose, although deviations from linearity may be observed at higher doses [54] . Nevertheless the low-dose effects are more relevant to human exposure scenarios than the high-dose effects, which may be explained in part by the influence of toxicity.
Methods for adduct detection
A number of sensitive methods have been developed for the detection and characterisation of DNA adducts (Table 3 ) [54; 55] . For an assay to be applicable to human exposure, it must (i) be sensitive enough to detect low levels of adducts; (ii) require only microgram quantities of DNA;
(iii) provide results quantitatively related to the exposure; (iv) be applicable to unknown adducts that may be formed from complex mixtures; and (v) be able to resolve, quantitate and identify adducts.
Most of the early work on adducts required the use of radiolabelled compounds (labelled either with 3 H or 14 C) at a position of the molecule where the isotope is not lost during metabolic activation and binding to DNA [55] . The DNA binding is then measured by the detection of radioactivity in DNA isolated from exposed animals or cells in culture achieving sensitivities of detection of 1 adduct in 10 8 nucleotides with 3 H-labelling, although 14 C-labelling is less sensitive due to the lower specific activity of 14 C-labelled compounds compared with 3 H-labelled ones (a consequence of the much longer half-life of 14 C compared with that of 3 H) [55] . However, due to the highly radioactive test compounds it was not possible to use this approach in studies involving humans.
In 1981, the 32 P-postlabelling technique was developed [56] [57] [58] . The method comprises a 4step process that involves (i) DNA digestion, (ii) a procedure that isolates or selects the adducts for preferential labelling, (iii) the introduction of a radiolabel into the DNA adducts using enzymatic [ 32 P]phosphorylation of the nucleotide adduct and (iv) separation of the 32 P-labelled adducts using thin layer (TLC) or high performance liquid chromatography (HPLC) [59; 60] . The assay requires only small (1-10 µg) quantities of DNA and is capable of detecting adducts at frequencies as low as 1 adduct in 10 10 nucleotides, making it widely applicable in human biomonitoring [61] . It can be used for a wide variety of classes of compounds, including polycyclic aromatic hydrocarbons (PAHs), aromatic and heterocyclic amines, unsaturated aldehydes, simple alkylating agents, reactive oxygen species, ultraviolet light (UV) radiation, and for the detection of adducts formed by complex mixtures [54; 62] . A limitation of the method is that it does not provide structural information; identification of adducts is reliant on co-chromatography using characterised synthetic standards [59] . A different approach using a similar experimental protocol is the chemical linkage of a fluorescent dye (e.g. BODIPY) to the DNA adducts, which can subsequently be separated by capillary electrophoresis and detected by laser-induced fluorescence (CE-LIF) [63] . Although this methodology is not yet sensitive enough to be applied to human samples (detection limit 1 adduct per 10 7 nucleotides) [63; 64] , it has proved to be a suitable technique to determine global DNA methylation levels [65] .
Mass spectrometry (MS) coupled with liquid-chromatography-electrospray ionisation spectrometry (ESI-LC-MS) is becoming used increasingly for the detection of DNA adducts
providing unequivocal identification of the nature of an adduct [55; 66; 67] . The sensitivities achieved are normally lower than with 32 P-postlabelling but, with the detection of 1 adduct per 10 8 to 10 9 nucleotides using 50-100 µg of DNA, they are sufficient to give useful data on human environmental or dietary exposures [67] . Accurate quantitation of DNA adduct levels is achieved by the use of a stable isotope internal standard (e.g. labelled either with 15 N or 13 C). Although mostly applied to the detection of specific well-characterised lesions, more recent techniques allow for the simultaneous detection of multiple adducts, and this 'adductome' approach has potential for the detection and characterisation of DNA adducts in human tissues [68] . Accelerator mass spectrometry (AMS), which measures isotope ratios, represents the most sensitive analytical method so far for detecting DNA adducts, with limits of adduct detection as low as 1 adduct in 10 11 nucleotides [66; 69] . The main limitation of the technique is that it depends on the presence of an isotope such as 14 Other physicochemical methods for the detection of DNA adducts are based on the fact that some adducts are highly fluorescent, enabling their detection by fluorescence spectroscopy [55; 72] .
Combining the fluorescent characteristics (specific excitation and emission wavelengths) with HPLC separation techniques make it even possible to detect stereoisomers. Adducts with fluorescent properties include those formed by PAHs and aflatoxins, cyclic (etheno) adducts, and some methylated adducts [72] . Other adducts, notably 8-oxo-dGuo, are readily detected by HPLC coupled with electrochemical detection (ECD) [73] . All these methods can provide a sensitivity of detection of around 1 adduct per 10 8 nucleotides, while requiring relative large quantities (100-1000 µg) of sample DNA. Overall, the major limitations of these methods are the required spectral (e.g. intrinsic fluorescence) and physicochemical properties of the adducts.
Immunoassays have also been used for the detection of DNA adducts in human and experimental samples [74; 75] . Antibodies have been raised against a variety of carcinogenmodified DNAs, including those containing adducts of PAHs, aromatic amines, methylating agents, tamoxifen, UV radiation, and oxidative damage. Immunoassays are highly sensitive, but have generally been less sensitive than 32 P-postlabelling and usually require more DNA for analysis, although some recent developments have both increased sensitivity and reduced the amount of DNA required, improving the sensitivity to a level closer to that of 32 P-postlabelling [76] . When combined with histochemistry, cell-specific localisation of adducts in paraffin-embedded tissue is possible [77; 78] . However, antibodies can show cross-reactivity with adducts formed by the same class of compounds, which can obscure both the nature of the adducts and the levels at which they are present.
Biological significance of DNA adducts
While it is evident that DNA damage and binding by carcinogens occurs in the early, initiating stages of carcinogenesis, it has become increasingly clear that damage to DNA is also a feature of later stages of the multistage process, now that it is known that mutations in some genes are associated with later stages of progression of some types of tumour. It is also evident that the formation of DNA adducts is by no means a sufficient event for carcinogenesis, , as DNA adducts are frequently detectable in both target and non-target tissues. Nevertheless, inhibition of DNA adduct formation will decrease the incidence of tumours formed subsequently, and increasing the adduct levels generally leads to a higher tumour yield. Other evidence that strongly links DNA adduct formation to tumour initiation is the demonstration that XPA knockout mice, which are deficient in nucleotide excision repair, are highly sensitive to tumour induction by carcinogens that form stable adducts that would be removed from DNA in normal mice by this repair mechanism [79] .
That chemical modification of DNA can result in the same alterations as observed in mutated genes in tumours was observed with the H-ras-1 proto-oncogene transfected into NIH3T3 cells [80] . Prior modification (by reaction with benzo[a]pyrene diol-epoxide, BPDE, the reactive metabolite of benzo[a]pyrene; see Figure 1 ) of the plasmid containing the gene resulted in mutations occurring in the DNA after transfection and replication of the host cells, manifested as the appearance of transformed foci. Mutations that activate proto-oncogenes such as ras genes occur in a few codons in the gene, so correlations between the sites of mutations in such experiments may not be very informative. In contrast, for tumour suppressor genes there may be many possible sites of DNA damage and mutation that can lead to altered function of the gene product that contributes to malignant transformation. Such a gene is TP53, which has been found to be mutated in ~50% of human tumours. Correlations can be usefully sought between the mutation spectra observed in different human tumours in order to provide clues to the nature of the initiating agent(s) [81] . This approach has led to evidence for the involvement of the mycotoxin aflatoxin B 1 in the initiation of liver cancer in regions of high incidence in China, where a G→T transversion in codon 249 of TP53 is a common mutation in the disease [82] . In lung cancer, codons 157, 248 and 273 of the gene are frequently mutated; G→T transversions are much more common in cases of lung cancer among smokers than among non-smokers, and these types of mutation are characteristic of bulky carcinogens, such as the PAHs, which are present in tobacco smoke. When the sites of DNA adduct formation by BPDE in the TP53 gene in HeLa cells and bronchial epithelial cells were determined, it was found that codons 157, 248 and 273 were preferentially modified, correlating with the frequently mutated sites in lung tumours of smokers [83] .
UV causes DNA damage chiefly by dimerisation of adjacent pyrimidines in the same DNA strand. The biological importance of these lesions is illustrated by the fact that sufferers of Xeroderma Pigmentosum (XP), who have a deficiency in nucleotide excision repair mechanisms that remove pyrimidine dimers and other bulky adducts from DNA (also deficient in XPA knockout mice mentioned above), are prone to sunlight-induced skin cancer. Moreover, the type of TP53 mutation found commonly in such tumours, but rarely in tumours of internal organs, is a tandem mutation occurring at pyrimidine pairs (CC→TT transitions), highly suggestive that it arose from UV-induced pyrimidine dimers [84] .
Thus, there are examples of genetic changes in tumours that closely match the genetic changes that can be induced experimentally in cellular DNA by specific genotoxic agents. These tumour-specific mutations in TP53 and the demonstration that chemically-modified DNA transforms cells show that the mutations observed in human tumours could have arisen from the formation of carcinogen-DNA adducts in vivo. Clonal expansion of the mutated cells and the acquisition of further genetic alterations eventually leads to malignancy [3] .
Adducts as biomarkers of occupational and environmental exposure to carcinogens
Sensitive DNA adduct detection methods, not requiring the use of radiolabelled carcinogens, make it possible to monitor DNA isolated from human tissues for evidence of prior exposure to carcinogens. Many different tissues have provided DNA for such studies [85] , including blood, sputum, buccal mucosa, cervical mucosa, sperm, bladder (exfoliated urothelial cells in urine), placenta and hair roots. DNA from these accessible sources of human cells have been used in many studies, but by far the most commonly used tissue source has been blood cells (either lymphocytes or the whole fraction of nucleated white blood cells). While these are not target cells for malignancy, they are useful surrogates and are known to display evidence of genotoxic exposure using other, less sensitive, endpoints, such as micronucleus formation, chromosomal aberrations and mutation in reporter genes such as HPRT.
Heavy industries where an increased risk of lung and other cancers has been observed include iron and steel production, aluminium production, coke ovens and graphite electrode manufacture. The principal genotoxic exposure in these industries is to PAHs. Many studies have investigated DNA adduct formation in workers in these industries, using white blood cells as the monitored tissue. In general, the results of such studies have been the demonstration of statistically significant increases in the level of DNA adducts in the exposed workers, compared with controls [86] . Other industrial workforces studied, with similar results, include roofers, chimney sweeps, incinerator workers, petrol refinery workers, traffic police and bus maintenance workers [86] .
DNA adduct detection can also be used to investigate environmental exposure to genotoxic carcinogens [86] . For example, chronic environmental exposure to industrial sources of carcinogens has occurred in Upper Silesia and the Krakow region of Poland, and in Northern Bohemia in the Czech Republic. Studies on these populations have revealed significantly elevated levels of DNA adducts in blood cells compared with control populations from rural areas of the same countries. In Xuan Wei province of China, the practice of using smoky coal for cooking and heating in unventilated houses leads to a high level of smoke indoors and high incidences of lung cancer, particularly in the women (very few of whom smoke tobacco). Placental, blood and lung (from bronchoalveolar lavage) cells have all been used as sources of DNA to compare exposed female residents of Xuan Wei with a control group from Beijing, and in each case evidence for elevated levels of adducts was obtained [87] . In Henan province of China, there is an exceptionally high prevalence of oesophageal cancer and, among several suspected environmental factors, the high content of PAHs in the diet has recently become of interest; evidence that this may play a role in the aetiology of the disease is supported by the observation of high levels of PAH-DNA adducts, detected by immunohistochemistry, in archived surgical specimens of oesophagi from the region [88] .
A recent example of the identification of a human carcinogen is aristolochic acid (AA), a constituent of plants of the genus Aristolochia. AA is genotoxic, being positive in many short-term tests, and forms covalent DNA adducts in tissues of rodents, and in human cells in culture [89] . An outbreak of renal failure, followed by urothelial cancer in some of the patients, occurred among individuals in Belgium who took a slimming regimen containing Chinese herbs, one of which turned out to be an Aristolochia species. 32 P-Postlabelling analysis of DNA from the tissues of these patients revealed the presence of AA-DNA adducts, implicating the compound as the genotoxic agent involved in the carcinogenic process leading to urothelial tumours [90] . The renal disease, now known as Aristolochic acid nephropathy (AAN), is pathologically similar to Balkan endemic nephropathy (BEN), in which AA is also implicated [91] . The source is thought to Aristolochia clematitis, which grows wild in the Balkans and whose seeds may contaminate wheat flour in the region. The detection of AA-DNA adducts in renal tissues from BEN sufferers provides strong evidence for the involvement of AA in the aetiology of the disease [92] . Furthermore, analysis of TP53 mutations in BEN tumours, and in one AAN tumour, shows a preponderance of AT-TA transversion mutations, which is the predominant mutation that AA causes in experimental studies [92] [93] .
The relationship between DNA adduct formation and tobacco smoking has been widely studied and used to validate the biomarker (see below). Tobacco smoke contains at least 50 compounds that are known to be carcinogenic, including representatives of several distinct classes of compounds (PAHs, aromatic amines, N-nitrosamines, aza-arenes, aldehydes, other organic compounds and inorganic compounds). Most of these compounds are genotoxic carcinogens that form DNA adducts. In many studies that have compared DNA from smokers, ex-smokers and nonsmokers, higher levels of adducts have been found in many target tissues of smokers: lung, bronchus, larynx, bladder, cervix and oral mucosa [94] . In some of these studies a linear correlation between estimated tobacco smoke exposure and adduct levels has been observed. In tissues of the respiratory tract adduct levels in ex-smokers tend to be intermediate between smokers and nonsmokers, indicating that adducts are removed through DNA repair and/or cell turnover. The half-life of adduct persistence appears to be between one and two years.
For some of these studies specific adducts have been detected, but in others a more general measure of DNA damage has been made, namely aromatic/hydrophobic adducts detected by 32 Ppostlabelling, or PAH-DNA adducts detected by immunoassay. Recent studies have found that when adduct levels are adjusted to take account of the level of tobacco smoke exposure, lung DNA from women smokers is more highly adducted that that of male smokers. This finding is interesting in view of epidemiological evidence suggesting that women are at a 1.5-2-fold greater risk of lung cancer from smoking. It would appear that the adduct analysis provides biochemical, mechanistic evidence to support the morbidity data [95] .
Some, but not all, studies have shown elevated levels of lung adducts in cancer cases compared with controls. The relationship between adduct levels in target tissues (e.g. lung) and other tissues (e.g. blood) has been investigated to see whether the latter can serve as a valid accessible surrogate source of DNA for the former. Results for smoking-related adducts have been inconsistent [54; 96] , perhaps because other sources of exposure to some classes of carcinogens, such as PAHs, which are also ingested as dietary contaminants, may contribute to the overall level of adducts in the blood but not to the same extent in the lung.
DNA adducts in prospective studies
When measuring adducts in smokers at the time of cancer diagnosis (e.g. in case-control studies), investigators are not looking at the biochemical events causal in the initiation of those tumours, as these would have occurred decades earlier. However, because smoking is addictive and habitual for the vast majority of tobacco users, DNA adducts in tumour-adjacent tissue at the time of tumour manifestation can still serve as a useful biomarker that gives an indication of an individual's probable steady-state level of DNA damage maintained over a long period of time. In order to determine whether DNA adducts have predictive value in cancer risk, it is necessary to conduct prospective studies in which DNA samples are collected and stored from a large cohort of individuals who are then followed up to determine who does and who does not develop cancer in the future. It is then possible to perform a nested case-control study within the cohort to determine whether DNA adduct analysis of the stored samples reveals whether differences between the two groups were evident prior to the onset of disease.
The first example of this approach was a study conducted in Shanghai, China, where a high incidence of liver cancer is associated with dietary exposure to aflatoxin B 1 , 18, 244 men provided a single urine sample and provided detailed dietary questionnaire data, in addition to which food analyses were carried out [97] . When 55 cases of liver cancer subsequently arose in the cohort, these were matched to 267 disease-free controls and their urine samples analysed by HPLCfluorescence to detect the presence of aflatoxin derivatives. A significant association was found between the presence of aflatoxin metabolites, including the aflatoxin-N 7 -guanine adduct, and liver cancer. Interestingly, when data obtained from questionnaires and food analyses were considered without the biomarker data, no association between exposure and liver cancer was evident. Thus in this case the power of biomarkers of exposure showed a clear advantage over more traditional means of exposure assessment to show a causal association.
The ability of DNA adducts to predict lung cancer risk was investigated in tobacco smokers [98] . From a follow-up of a cohort of 15, 700 males who had provided blood samples at the outset of the study, 93 cases of lung cancer were identified and matched to 173 controls. Analysis of white blood cell DNA by 32 P-postlabelling revealed that smokers who got lung cancer had 2-fold higher levels of bulky/hydrophobic DNA adducts than smokers who did not. The smokers who had elevated levels of adducts were approximately three times more likely to be diagnosed with lung cancer 1-13 years later than the smokers with lower adduct concentrations.
The predictive power of DNA adducts to distinguish groups of individuals who developed cancer from those who did not was also investigated in two recent studies that measured bulky DNA adducts in leukocytes by 32 P-postlabelling analysis. In the first, 115 cases of lung cancer were matched with twice the number of controls from European cohorts totalling more than 500, 000 people [99] . Detectable DNA adducts were significantly more common in non-smokers and longterm ex-smokers who developed lung cancer than in those who did not. The second study investigated 245 individuals with lung cancer and 255 without, from a population-based cohort of 53, 689 men and women [100] . The median level of DNA adducts was significantly higher for smokers who developed lung cancer than for those that did not. Although adduct levels were statistically significantly higher in the cases in both these studies, the numerical differences from the controls was somewhat small. Thus the ability to predict cancer risk from DNA adduct measurements on an individual basis will be very limited, despite the collective differences between the cases and the controls. Nevertheless, DNA adduct analysis should have applications in investigating the efficacy of chemoprevention strategies by, for example, documenting a reduction in adduct levels concomitant with a reduction in cancer risk in interventions in an occupationally-or environmentally-exposed population.
Summary
DNA adduct formation, or the causation of DNA damage by less direct means, is an important property of genotoxic agents. The strategies that have been developed for determining the carcinogenic potential of chemicals, using short-term tests, are based on detecting evidence of either DNA damage or its biological consequences. Although it is well recognised that the carcinogenic activity of some chemicals is the result of non-genotoxic mechanisms, the majority of known human carcinogens are genotoxic. Early studies on DNA adducts required use of radioactively labelled compounds, but alternative methods with a high degree of sensitivity and selectivity have since been developed, enabling their wider application, including the monitoring of human exposure to environmental carcinogens and in providing clues to the aetiology of some cancers. Experimental interventions that reduce DNA adduct formation also reduce carcinogenicity, while enhancing DNA adduct formation has the opposite effect. In prospective studies, elevated DNA adducts have been found in individuals who subsequently developed cancer relative to those who did not. Continuing research into the detection and characterisation of DNA adducts in human tissues will shed further light on the causative agents of human cancers. 
